Aniruddh P Patel1,2,3,4,5, Minxian Wang (汪敏先)4,5, James P Pirruccello1,2,3,4,5, Patrick T Ellinor1,2,3,4,5, Kenney Ng6, Sekar Kathiresan1,2,3,4,7, Amit V Khera1,2,3,4,5. 1. Center for Genomic Medicine (A.P.P., J.P.P., P.T.E., A.V.K.), Massachusetts General Hospital, Boston. 2. Division of Cardiology, Department of Medicine (A.P.P., J.P.P., P.T.E., S.K., A.V.K.), Massachusetts General Hospital, Boston. 3. Department of Medicine, Harvard Medical School, Boston, MA (A.P.P., J.P.P., P.T.E., S.K., A.V.K.). 4. Cardiovascular Disease Initiative (A.P.P., M.W., J.P.P., P.T.E., S.K., A.V.K.), Broad Institute of MIT and Harvard, Cambridge, MA. 5. Program in Medical and Population Genetics (A.P.P., M.W., J.P.P., P.T.E., A.V.K.), Broad Institute of MIT and Harvard, Cambridge, MA. 6. Center for Computational Health, IBM Research, Cambridge, MA (K.N.). 7. Verve Therapeutics, Cambridge, MA (S.K.).
Abstract
OBJECTIVE: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th-75th percentile 7.6-74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10-1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race-median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar-hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44-1.56) and 1.16 (95% CI, 1.05-1.27), respectively. CONCLUSIONS: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.
OBJECTIVE: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th-75th percentile 7.6-74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10-1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race-median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar-hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44-1.56) and 1.16 (95% CI, 1.05-1.27), respectively. CONCLUSIONS: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.
Authors: Sotirios Tsimikas; Emmanouil S Brilakis; Elizabeth R Miller; Joseph P McConnell; Ryan J Lennon; Kenneth S Kornman; Joseph L Witztum; Peter B Berger Journal: N Engl J Med Date: 2005-07-07 Impact factor: 91.245
Authors: Peter Willeit; Paul M Ridker; Paul J Nestel; John Simes; Andrew M Tonkin; Terje R Pedersen; Gregory G Schwartz; Anders G Olsson; Helen M Colhoun; Florian Kronenberg; Christiane Drechsler; Christoph Wanner; Samia Mora; Anastasia Lesogor; Sotirios Tsimikas Journal: Lancet Date: 2018-10-04 Impact factor: 79.321
Authors: Guillaume Paré; Artuela Çaku; Matthew McQueen; Sonia S Anand; Enas Enas; Robert Clarke; Michael B Boffa; Marlys Koschinsky; Xingyu Wang; Salim Yusuf Journal: Circulation Date: 2019-03-19 Impact factor: 29.690
Authors: Sotirios Tsimikas; Paul Clopton; Emmanouil S Brilakis; Santica M Marcovina; Amit Khera; Elizabeth R Miller; James A de Lemos; Joseph L Witztum Journal: Circulation Date: 2009-03-23 Impact factor: 29.690
Authors: Robert Clarke; John F Peden; Jemma C Hopewell; Theodosios Kyriakou; Anuj Goel; Simon C Heath; Sarah Parish; Simona Barlera; Maria Grazia Franzosi; Stephan Rust; Derrick Bennett; Angela Silveira; Anders Malarstig; Fiona R Green; Mark Lathrop; Bruna Gigante; Karin Leander; Ulf de Faire; Udo Seedorf; Anders Hamsten; Rory Collins; Hugh Watkins; Martin Farrall Journal: N Engl J Med Date: 2009-12-24 Impact factor: 91.245
Authors: Connor A Emdin; Amit V Khera; Pradeep Natarajan; Derek Klarin; Hong-Hee Won; Gina M Peloso; Nathan O Stitziel; Akihiro Nomura; Seyedeh M Zekavat; Alexander G Bick; Namrata Gupta; Rosanna Asselta; Stefano Duga; Piera Angelica Merlini; Adolfo Correa; Thorsten Kessler; James G Wilson; Matthew J Bown; Alistair S Hall; Peter S Braund; Nilesh J Samani; Heribert Schunkert; Jaume Marrugat; Roberto Elosua; Ruth McPherson; Martin Farrall; Hugh Watkins; Cristen Willer; Gonçalo R Abecasis; Janine F Felix; Ramachandran S Vasan; Eric Lander; Daniel J Rader; John Danesh; Diego Ardissino; Stacey Gabriel; Danish Saleheen; Sekar Kathiresan Journal: J Am Coll Cardiol Date: 2016-12-27 Impact factor: 24.094
Authors: Luís Meira-Machado; Carmen Cadarso-Suárez; Francisco Gude; Artur Araújo Journal: Comput Math Methods Med Date: 2013-12-12 Impact factor: 2.238
Authors: Rutger Verbeek; Renate M Hoogeveen; Anne Langsted; Lotte C A Stiekema; Simone L Verweij; G Kees Hovingh; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Børge G Nordestgaard; Erik S G Stroes Journal: Eur Heart J Date: 2018-07-14 Impact factor: 29.983
Authors: Lisandro D Colantonio; Vera Bittner; Monika M Safford; Santica Marcovina; Todd M Brown; Elizabeth A Jackson; Mei Li; J Antonio G López; Keri L Monda; Timothy B Plante; Shia T Kent; Paul Muntner; Robert S Rosenson Journal: J Am Heart Assoc Date: 2022-05-27 Impact factor: 6.106
Authors: Benjamin A Satterfield; Ozan Dikilitas; Maya S Safarova; Shoa L Clarke; Catherine Tcheandjieu; Xiang Zhu; Lisa Bastarache; Eric B Larson; Anne E Justice; Ning Shang; Elisabeth A Rosenthal; Amy Sanghavi Shah; Bahram Namjou-Khales; Elaine M Urbina; Wei-Qi Wei; QiPing Feng; Gail P Jarvik; Scott J Hebbring; Mariza de Andrade; Teri A Manolio; Themistocles L Assimes; Iftikhar J Kullo Journal: Circ Genom Precis Med Date: 2021-07-20